Peptide Reconstitution: The Complete Dosing Guide for BPC-157, TB-500, and GHK-Cu

The core answer

Reconstitution concentration equals the total micrograms in the vial divided by the milliliters of bacteriostatic water added, and the volume to draw for any target dose equals that dose divided by the resulting concentration. For a 5,000 mcg vial mixed with 2 mL of bacteriostatic water (2,500 mcg/mL), a 250 mcg dose requires 0.1 mL, or 10 units on a U-100 insulin syringe. This math applies equally to BPC-157 and TB-500 vials sold as unapproved research chemicals, and to compounded GHK-Cu prepared by a licensed pharmacy; it does not by itself establish that any particular dose is safe, effective, or appropriate for a given person, because BPC-157 and TB-500 have not completed the human trials that would answer that question.

What these three peptides actually are

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) modeled on a fragment found in gastric juice. It has no FDA-approved indication. Available evidence is almost entirely from animal and in vitro studies of tendon, ligament, and gut healing; controlled human trials have not been completed, so human efficacy and long-term safety are not established.

TB-500 is marketed as a synthetic fragment related to thymosin beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation and tissue repair signaling. It also has no FDA-approved indication, and it appears on anti-doping prohibited lists for peptide hormones and growth factors, so athletes subject to testing should not use it.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma. Unlike the other two, it has a legitimate regulatory home as a cosmetic ingredient in topical products, and a separate, more restricted pathway as a compounded injectable prepared by a licensed pharmacy under prescription. These are two different regulatory categories and should not be conflated: a topical serum bought online is not the same product, oversight, or evidence base as an injectable compounded by a pharmacy for a specific patient.

Why the math matters more than the marketing

Getting the concentration formula wrong by a decimal point produces a ten-fold dosing error in either direction. The formula:

mcg/mL = total mcg in vial ÷ mL of bacteriostatic water added

Worked example: a 5 mg (5,000 mcg) vial with 2 mL of bacteriostatic water added yields 5,000 ÷ 2 = 2,500 mcg/mL. On a U-100 insulin syringe (100 units = 1 mL, so 1 unit = 0.01 mL), that concentration delivers 25 mcg per unit. A 250 mcg dose is drawn to the 10-unit mark.

The same three steps apply to any peptide vial:

1. Convert the vial's labeled amount to micrograms (5 mg = 5,000 mcg; 10 mg = 10,000 mcg).
2. Divide by the milliliters of bacteriostatic water added to get mcg/mL.
3. Divide the target dose in mcg by that concentration to get the volume in mL, then multiply by 100 for U-100 syringe units.

Worked example, BPC-157: 5,000 mcg vial, 2 mL BW added → 2,500 mcg/mL. A 300 mcg dose = 300 ÷ 2,500 = 0.12 mL = 12 units.

Worked example, TB-500: 5,000 mcg vial, 2 mL BW added → 2,500 mcg/mL. A 2,000 mcg dose = 2,000 ÷ 2,500 = 0.8 mL = 80 units.

Self-administered injectable medications carry a recognized risk of unit-conversion and measurement error in the general injection-safety literature; the exact error rate for peptide research compounds specifically has not been established in the sources reviewed for this page, and a precise percentage should not be treated as confirmed until traced to its original study.

BPC-157: reconstitution and the doses seen in practice

Standard research vials are commonly labeled 5 mg (5,000 mcg).

Typical reconstitution steps:

1. Draw 1 to 2 mL of bacteriostatic water into a syringe.
2. Insert the needle through the vial septum at an angle.
3. Inject the water slowly down the inside wall of the vial rather than directly onto the powder.
4. Swirl gently, do not shake, until fully dissolved; the solution should be clear and colorless.
5. Label the vial with the reconstitution date and resulting concentration.

Doses reported in the compounding and clinician-protocol literature for BPC-157 commonly fall in a 200 to 500 mcg per injection range, once or twice daily, injected subcutaneously. This range comes from clinical practice patterns and animal-study dose extrapolation, not from a completed human dose-ranging trial, and readers should not treat it as a validated therapeutic dose. Because no large human trials exist, questions about the right dose, duration, or injection site for a specific injury belong to a prescribing clinician, not to a generic guide.

TB-500: reconstitution and typical protocol structure

Standard vials are commonly labeled 5 mg (5,000 mcg).

Protocols described in clinical peptide practice commonly use a loading phase (roughly 2 to 2.5 mg twice weekly for several weeks) followed by a maintenance phase (roughly 2 mg once weekly). These figures reflect practice patterns rather than a regulator-reviewed label or a completed efficacy trial, and individual protocols vary by prescriber, indication, and body weight. TB-500 has no FDA-approved indication and is listed by anti-doping authorities among prohibited peptide hormones and growth factors; anyone subject to sport drug testing should not use it.

GHK-Cu: two different products, two different evidence bases

Topical GHK-Cu is the better-studied form. Small controlled trials have reported improvements in measures of skin texture and density with topical GHK-Cu formulations over several weeks, though exact effect sizes vary by study and should be verified against the primary trial before being quoted as a guarantee. Typical topical concentrations range from 0.1% to 1% (weight/volume); a 1% solution contains 10 mg per mL. Scalp formulations for hair density typically use lower concentrations, around 0.1 to 0.2%.

Injectable GHK-Cu is a compounded pharmacy product requiring a physician prescription in the United States. Compounded vials are commonly 50 mg or 100 mg. For a 50 mg vial with 10 mL of bacteriostatic water added: 50,000 ÷ 10 = 5,000 mcg/mL. A 1 mg (1,000 mcg) dose draws to the 20-unit mark; a 2 mg (2,000 mcg) dose draws to the 40-unit mark. Practice-pattern doses commonly cited are 1 to 2 mg subcutaneously, three to five times weekly, but this again reflects compounding-pharmacy and prescriber practice rather than an FDA-reviewed dosing label.

GHK-Cu route selection: what the goal implies about the route

The dividing line is not "which is stronger" but "which regulatory and evidence category applies." A topical serum bought without a prescription is a cosmetic-category product; an injectable requires pharmacy compounding and a diagnosis-specific prescription, and switching from one to the other is a decision for a prescriber, not a self-directed escalation.

Diluent choice

Bacteriostatic water (0.9% benzyl alcohol) is the standard diluent for BPC-157, TB-500, and most compounded GHK-Cu because the preservative allows repeated draws from one vial over a period commonly cited as up to 30 days when refrigerated. Sterile water for injection contains no preservative and should be treated as single-use, discarded within 24 hours of reconstitution. General injection-safety guidance from the CDC advises against reusing single-dose vials while permitting properly preserved multi-dose vials to be used across multiple draws; that general principle applies here even though CDC guidance is not peptide-specific.

Acetic acid (around 0.6%) is sometimes used for peptides that do not dissolve well in neutral water, such as some growth-hormone-releasing hormone analogs; it is not typically needed for BPC-157, TB-500, or GHK-Cu. Normal saline is occasionally used but is not preferred for multi-dose vials because it lacks the preservative properties of bacteriostatic water.

Clean the vial septum with a 70% isopropyl alcohol swab and let it dry before each draw. Injecting the diluent down the side of the vial rather than directly onto the powder reduces foaming, which can otherwise disrupt the peptide.

Storage, stability, and signs a vial should be discarded

Unreconstituted lyophilized powder, stored dry and protected from light, is generally considered stable for many months, though exact shelf life depends on the specific peptide and manufacturer packaging. Once reconstituted:

• Refrigerate at 2 to 8 °C immediately; do not freeze, since ice crystal formation can disrupt the peptide's structure.
• Vials reconstituted with bacteriostatic water are commonly used within about 30 days.
• Vials reconstituted with plain sterile water should be used within 24 hours.
• Discard any solution that turns cloudy, develops particulates, or changes color. BPC-157, TB-500, and GHK-Cu solutions are normally clear (GHK-Cu may carry a faint blue tint from its copper complex).
• Keep vials away from direct light. Peptide bonds are generally light-sensitive, and prolonged UV exposure is reported to reduce potency, though a specific percentage figure for these particular compounds requires verification against the original study before being repeated as fact.

Syringe and injection technique

A standard U-100 insulin syringe holds 1 mL marked in 100 units (1 unit = 0.01 mL), which fits the volumes used for BPC-157, TB-500, and injectable GHK-Cu. Needles in the 27G to 31G range, roughly 5/16 inch (8 mm), are typical for subcutaneous injection in the abdomen or thigh; shorter 4 mm pen needles may suit leaner individuals.

General subcutaneous technique: wash hands, clean the site with alcohol and let it dry, pinch a fold of skin, insert the needle at an angle appropriate to tissue depth, inject slowly, withdraw without rubbing the site, and rotate injection sites to avoid localized tissue changes over repeated use. These are general subcutaneous-injection practices, not instructions specific to any one peptide's pharmacology.

What is established, what is plausible, and what is not established

Established: The reconstitution arithmetic (mcg in vial ÷ mL diluent = concentration; dose ÷ concentration = volume) is basic pharmaceutical math and does not depend on which peptide is in the vial. Bacteriostatic water with benzyl alcohol is a recognized preservative-containing diluent appropriate for multi-dose use. GHK-Cu is a recognized cosmetic ingredient with some controlled topical trial data. BPC-157 and TB-500 have no FDA-approved human indication.

Plausible but not established in humans: That the animal-study dose ranges for BPC-157 and TB-500 translate directly to safe or effective human doses. That subcutaneous and intramuscular routes are truly bioequivalent for these peptides in people. That the specific loading/maintenance schedules circulating in practice represent an optimized regimen rather than an inherited convention.

Not established: Long-term safety of repeated BPC-157 or TB-500 use in humans, since large controlled human trials have not been completed. The purity, sterility, and labeled concentration accuracy of peptides purchased from unregulated research-chemical vendors, which is a separate risk from the reconstitution math itself.

Legal and safety context

BPC-157 and TB-500 are sold as research chemicals for laboratory use and are not FDA-approved drugs; using them as an injectable therapy in a person falls outside standard, FDA-reviewed medical practice. GHK-Cu's injectable form requires a valid prescription and pharmacy compounding in the United States. The FDA maintains a public warning-letter database that includes actions against vendors marketing unapproved peptide products with unsubstantiated claims, and checking a vendor's regulatory history there before purchasing is a reasonable verification step.

Professional endocrine guidance generally cautions that peptide therapies marketed for performance or recovery carry limited human safety and efficacy data outside of approved indications or registered clinical trials; readers should consult current guidance directly at endocrine.org rather than relying on a paraphrased summary for specifics, since the exact wording of any position statement should be read in its original context rather than quoted secondhand.

Contamination, incorrect labeled concentration, and mislabeled contents are documented risks with unregulated research-chemical vendors, independent of whether the reconstitution math is done correctly. A physician-prescribed, pharmacy-compounded product carries sterility and potency testing that self-sourced vials do not.

When to seek urgent care rather than troubleshoot at home: fever, spreading redness, warmth, or pus at an injection site; difficulty breathing, facial swelling, or hives after an injection; or any injection followed by symptoms that feel disproportionate to a routine subcutaneous shot. These are reasons to seek medical evaluation, not to adjust the next dose.

Clinician discussion and monitoring framework

Use this before starting, and at each check-in, to separate what a prescriber controls from what generic dosing information can and cannot answer.

Before the first dose, ask the prescriber:

• What is the source and quality verification for this specific vial (compounding pharmacy vs. research-chemical vendor)?
• What is the documented reason this peptide, route, and dose range is being used for my situation, given that BPC-157 and TB-500 have no FDA-approved indication?
• What baseline labs or exam findings, if any, are being checked before starting?
• What would count as "working" and by when should improvement be reassessed?

Checkpoint at 2 to 4 weeks:

• Any injection-site redness, swelling, or induration that has not resolved between doses.
• Any systemic symptoms (fever, unusual fatigue, rash) since starting.
• Confirm reconstitution technique and storage are still on track (correct refrigeration, vial not past its use window, solution still clear).
• Reassess whether the working definition of improvement from the first visit is being met.

Checkpoint at 8 to 12 weeks (if continuing):

• Reassess whether continued use is achieving the originally stated goal, or whether the goal should be revised.
• Ask whether ongoing use still matches current professional guidance, since guidance in this area can change.

Stop and escalate to urgent evaluation if:

• Fever, spreading redness, or pus at an injection site.
• Signs of an allergic reaction (hives, facial or throat swelling, difficulty breathing).
• New symptoms that are not explained by a routine injection and are worsening.

Boundary between label guidance and individualized care: Nothing in published guidance sets an FDA-reviewed dose for BPC-157 or TB-500 in humans, so any specific number in circulation, including the ranges summarized on this page, is a practice pattern, not a label instruction. Only a prescriber who has examined the patient and reviewed their history can turn a general range into an individual plan; a generic article cannot and should not be used as a substitute for that conversation.

References

3. CDC injection safety guidance on single-dose vs. multi-dose vials: https://www.cdc.gov/injectionsafety/providers/provider_faqs_multivials.html
4. Endocrine Society clinical practice guidelines (consult directly for current position on growth hormone secretagogues and related peptides): https://www.endocrine.org/clinical-practice-guidelines

A targeted search for recent primary literature specific to peptide reconstitution dosing and monitoring did not surface a directly relevant human trial; the closest available recent primary-source result concerned tumor-infiltrating lymphocyte therapy and IL-2 cardiac monitoring in melanoma, which addresses a different peptide/cell therapy context and does not support claims about BPC-157, TB-500, or GHK-Cu reconstitution or dosing, so it has not been cited here. Individual claims above tied to specific PubMed identifiers in prior versions of this article require verification against the original paper before any exact number is restated as established fact.